Predictive biomarkers of immunotherapy response are critical for clinical practice. In this study, baseline plasma sCD27 was ...

The claims of all three patents are directed to methods of treating cancer with the combination of two checkpoint inhibitor immunotherapeutic antibodies, anti-PD-1 and anti-CTLA-4.

First VISTA Inhibitor Drug Approval By 2028 Says Kuick Research In New Research Publication. Delhi, April 02, 2025 (GLOBE NEWSWIRE) -- Global VISTA Inhibitor Clini ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

These safety data continue to support the potential for vilastobart to be a differentiated next-generation anti-CTLA-4 in combination with PD-(L)1 inhibitors. For more information, read the press ...

MGNX earnings call for the period ending December 31, 2024. MacroGenics ( MGNX -14.87%) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of ...

Reports revenue $103,204 vs. $18.1M last year. “The clinical data we generated in 2024 with ADG126 gives us great confidence in our ability to ...